Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 infusion rate study in healthy volunteers
NCT02535416Phase 1Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of ARC-520 (9 cohorts), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events. Started Sep 2015; status: completed.
02
Drugs
ARC-520
Beyond the preview
Go deeper on NCT02535416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535416.